Off-Label Use Of Zometa For Osteoporosis Accounts For 5% Of Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis sees growth of Zometa in oncology despite financial incentives to prescribe generic bisphosphonates, North American Oncology Head Dunshire says. The company is on track to submit a once-yearly formulation of zoledronic acid for osteoporosis in 2007.